Navigation Links
Unique needs and outcomes of pregnant women with breast cancer identified
Date:12/11/2010

SAN ANTONIO Do not delay treatment of breast cancer just because a woman is pregnant, said lead researcher Sibylle Loibl, Dr. med, of the German Breast Group.

This suggestion is based on study results detailing the effects of different treatment options on the infant. Loibl presented this data at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.

"At the time we started the study in 2003, there was hardly any information on breast cancer therapy during pregnancy, but we felt there was a medical need for it," she said.

Although the incidence of pregnancy among breast cancer patients is small (about 2 to 3 percent), women are delaying childbirth until later in age, which may increase the instances of cancer cases among pregnant women, according to Loibl.

The researchers collected data from women diagnosed with breast cancer while pregnant to see how the infants fared.

From April 2003 until June 2010, they collected data from 313 women, aged 23 to 47 years old. The women had various subtypes of breast cancer, and the cancer was in various stages when diagnosed. All of the women were pregnant when they were diagnosed with cancer: 23 percent were in the first trimester, 42 percent were in the second and 36 percent were in the third trimester. Some women received various treatment regimens while the rest received chemotherapy.

Two of the infants died shortly after birth and 29 did not continue the pregnancy. Premature deliveries were more common among women who did not receive chemotherapy than among women who did receive chemotherapy. In addition, the infants of the women who received chemotherapy tended to weigh a little more than those who did not receive chemotherapy.

Infants from both groups experienced congenital problems, most of which were related to premature birth.

"We were surprised about the number of congenital malformations," Loibl said. "It is about 1 to 3 percent in the general population, but was higher in this cohort."

Although the study was primarily focused on the infant outcomes, the researchers also looked at the treatment effects on the women and found that the median overall disease-free survival of the mothers was 27 months and median overall survival was 55 months.

Based on these results Loibl said she would advise her pregnant cancer patients to "continue the pregnancy and start with a treatment as closely as possible to standard recommendations for nonpregnant women." In addition, it is critical that a multidisciplinary team in close collaboration with an obstetrician, prenatal care specialist and a neonatologist treat the pregnant woman with breast cancer.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Snakes on a rope: Researchers take a unique look at the climbing abilities of boa constrictors
2. New strain of high-runner rats uniquely resistant to disease -- all disease!
3. Unique database of cancer -- designed to personalize treatment -- is launched
4. Philippines may have more unique bird species: CCNY biologist
5. U of M licenses unique plant protection product
6. Scientists identify DNA that may contribute to each persons uniqueness
7. Montana State grad student to study unique soil around Yellowstone hot springs
8. Glaucomas unique protein expression could enhance diagnosis and treatment
9. Unique coral reef education pilot program to be conducted in the Bahamas
10. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
11. Pitt researchers report internal and environmental factors trigger unique brain activity in teens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology: